1) The blister protocol is being used to evaluate inflammation in vivo in several populations of patients with rare immunodeficiencies including STAT3 deficiency, CGD, and others. Our efforts to accrue subjects with CGD (currently n=3) in order to examine the development and progression of inflammation in vivo in this patient population have been slow. This year, we collaborated with the Human Immunologic Diseases Unit (LHD) to examine inflammation in a patient with a chemotactic defect. 2) Interferon-γ prophyaxis is an FDA-approved therapy for CGD however it causes significant flu-like symptoms in some patients and anecdotal reports suggest that it might not benefit all patients.
Aimi ng toward differentiating patients who may respond to IFNG from those who may not, we initiated a clinical protocol (#10-I-0123 Assessment of the Biochemical Response to IFN-gamma in Subjects with Specific Gene Mutations in Chronic Granulomatous Disease) in 2010. Due to the low level of patient interest in this time-intensive protocol, we have terminated this protocol (effective December, 2014) and are currently evaluating other approaches to address this important question

Project Start
Project End
Budget Start
Budget End
Support Year
28
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
Zip Code
Matharu, Kabir; Zarember, Kol A; Marciano, Beatriz E et al. (2013) B-cell activating factor (BAFF) is elevated in chronic granulomatous disease. Clin Immunol 148:258-64
Hsu, Amy P; Sowerwine, Kathryn J; Lawrence, Monica G et al. (2013) Intermediate phenotypes in patients with autosomal dominant hyper-IgE syndrome caused by somatic mosaicism. J Allergy Clin Immunol 131:1586-93
Zarember, Kol A; Kuhns, Douglas B (2011) Editorial: will the real neutrophil please stand up? J Leukoc Biol 90:1039-41
Laskey, Heather L; Gopal, Lakshmi; Gallin, John I et al. (2009) Twenty-year follow-up of esophageal involvement in chronic granulomatous disease. Am J Gastroenterol 104:2368-70
Singh, Anjali; Zarember, Kol A; Kuhns, Douglas B et al. (2009) Impaired priming and activation of the neutrophil NADPH oxidase in patients with IRAK4 or NEMO deficiency. J Immunol 182:6410-7
Isnardi, Isabelle; Ng, Yen-Shing; Srdanovic, Iva et al. (2008) IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 29:746-57